In early June, clinical results with BiPar's experimental drug BSI-201 and AstraZeneca's small-molecule PARP inhibitor olaparib were presented at the American Society of Clinical Oncology meeting ...

对肿瘤侵袭性特征的影响 ：研究发现，RS-35d 单独使用可显著降低 BxPC-3 细胞集落形成率，与 olaparib 联合使用时效果更显著。在伤口愈合实验中，RS-35d/olaparib、S-35d/olaparib 和 R-35d/olaparib 组合均能显著降低细胞迁移，但 RS-35d 单独使用时也有明显效果。通过流式细胞术分析凋亡发现，RS-35d/olaparib 和 S-35d ...

A retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category ... of several indications on the Lynparza (olaparib) label – that could lead to ...

PARP inhibitor Number of completed or ongoing studies Type of studies completed or ongoing Specific tissue cancers that were studied Combination therapy studied Olaparib (AZD2281) 52 Phase I ...

This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian ...

AZ will present new data on Merck & Co/MSD-partnered PARP drug Lynparza (olaparib) in ovarian, prostate and pancreatic cancer, while GSK will set out the case for Zejula (niraparib ...

We are getting questions from farmers and accountants wondering if Pandemic Assistance Revenue Program (PARP) payments are still going to be made in 2023. Many are tidying up taxes for 2023 ...